Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors (vol 27, pg 3620, 2021)

被引：1
|
作者：
Curigliano, Giuseppe
Curigliano, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 17期
关键词：
D O I：
10.1158/1078-0432.CCR-24-2131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3957 / 3957
页数：1
相关论文
共 50 条
  • [1] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
    Curigliano, Giuseppe
    Gelderblom, Hans
    Mach, Nicolas
    Doi, Toshihiko
    Tai, David
    Forde, Patrick M.
    Sarantopoulos, John
    Bedard, Philippe L.
    Lin, Chia-Chi
    Hodi, F. Stephen
    Wilgenhof, Sofie
    Santoro, Armando
    Sabatos-Peyton, Catherine A.
    Longmire, Tyler A.
    Xyrafas, Alexandros
    Sun, Haiying
    Gutzwiller, Sabine
    Manenti, Luigi
    Naing, Aung
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629
  • [2] Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
    Desai, Jayesh
    Meniawy, Tarek
    Beagle, Brandon
    Li, ZheZhen
    Mu, Song
    Wu, John
    Denlinger, Crystal S.
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
    Lakhani, N.
    Spreafico, A.
    Tolcher, A. W.
    Rodon, J.
    Janku, F.
    Chandana, S. R.
    Oliva, M.
    Sharma, M.
    Abdul-Karim, R. M.
    Hansen, U. H.
    Hansen, L.
    Skartved, N. J. O.
    Poulsen, T. T.
    Nadal, R. P.
    Lantto, J.
    Wood, D. L.
    Nadler, P. I.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S704 - S704
  • [5] A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
    Spreafico, A.
    Janku, F.
    Rodon, J. A.
    Tolcher, A. W.
    Chandana, S. R.
    Oliva, M.
    Musalli, S.
    Knauss, L.
    Kragh, M.
    Alifrangis, L.
    Frohlich, C.
    Melander, M. C.
    Blondal, T.
    Pedersen, M. W.
    Lantto, J.
    Wood, D.
    Nadler, P. I.
    Horak, I. D.
    Siu, L. L.
    Lakhani, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 488 - +
  • [6] A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors
    Weiss, Glen J.
    Luke, Jason J.
    Falchook, Gerald
    Eroglu, Zeynep
    Wang, Judy
    Hamilton, Erika
    Hecht, J. Randolph
    LoRusso, Patricia
    Eder, Joseph Paul
    Hughes, Lorraine
    Wang, Jing
    Running, Kelli
    McEachern, Kristen
    Bobilev, Dmitri
    Ribas, Antoni
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [7] THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Sun, H.
    Sy, S.
    Xu, J.
    Hara, H.
    Cameron, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S41 - S41
  • [8] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [9] THE RECOMMENDED PHASE II DOSE SELECTION FOR SPARTALIZUMAB (PDR001), AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Sun, H.
    Sy, S.
    Xu, J.
    Hara, H.
    Cameron, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S73 - S73
  • [10] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
12345